ACADIA Pharmaceuticals

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. The Company has a pipeline of product candidates led by NUPLAZID (pimavanserin) -  the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1993
Size (employees)
425 (est)+15%
ACADIA Pharmaceuticals was founded in 1993 and is headquartered in San Diego, US

ACADIA Pharmaceuticals Office Locations

ACADIA Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
3611 Valley Centre Dr, Suite 300

ACADIA Pharmaceuticals Financials and Metrics

ACADIA Pharmaceuticals Financials

ACADIA Pharmaceuticals's revenue was reported to be $17.3 m in FY, 2016
USD

Revenue (Q2, 2017)

30.5 m

Gross profit (Q2, 2017)

28.3 m

Gross profit margin (Q2, 2017), %

93%

Net income (Q2, 2017)

(67.4 m)

EBIT (Q2, 2017)

(68.4 m)

Market capitalization (13-Dec-2017)

3.7 b

Cash (30-Jun-2017)

143.8 m
ACADIA Pharmaceuticals's current market capitalization is $3.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.1 m120 k61 k17.3 m

Revenue growth, %

(90%)(49%)28311%

Cost of goods sold

3.1 m

Gross profit

120 k61 k14.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

97 k5.3 m15.3 m30.5 m

Cost of goods sold

526 k845 k2.3 m2.2 m

Gross profit

(429 k)4.4 m13 m28.3 m

Gross profit Margin, %

(442%)84%85%93%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.7 m61.9 m102.1 m163.6 m

Accounts Receivable

5.9 m

Inventories

1.2 m2.2 m4.2 m

Current Assets

188.4 m324.6 m219 m547.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

11.8 m96.5 m13.7 m36.4 m76.4 m93.2 m70.8 m175.2 m131.8 m153.7 m157.4 m143.8 m

Accounts Receivable

293 k3.8 m7.7 m11.6 m

Inventories

2.9 m4.3 m3.9 m6 m

Current Assets

198.7 m372.8 m358.9 m341.1 m299.9 m273.4 m242.8 m462.4 m423.9 m603.5 m489.8 m443.7 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(92.5 m)(164.4 m)(271.4 m)

Depreciation and Amortization

206 k647 k1.8 m

Accounts Receivable

(5.9 m)

Inventories

652 k(804 k)(3.3 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.7 m)(17.8 m)(21.5 m)(24.8 m)(40.4 m)(79.8 m)(118.7 m)(49.8 m)(71.3 m)(71.6 m)(87.8 m)

Depreciation and Amortization

402 k519 k

Accounts Receivable

293 k3.8 m7.7 m

Inventories

2.9 m4.3 m3.9 m
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

ACADIA Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

302
Show all operating metrics

ACADIA Pharmaceuticals Market Value History

ACADIA Pharmaceuticals's Web-traffic and Trends

ACADIA Pharmaceuticals Company Life and Culture

You may also be interested in